Barry L. Templin net worth and biography

Barry Templin Biography and Net Worth

EXECUTIVE VP, CHIEF TECHNOLOGY OFFICER of PROCEPT BioRobotics

Mr. Templin has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, he served as the VP of Clinical Research, Engineering, and Therapy Development for CardioKinetix. Prior to CardioKinetix, Mr. Templin was the Global Clinical Program Director for Abbott Vascular. He also led the landmark vulnerable plaque natural history study, PROSPECT. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines and Guidant, and then clinical positions with Guidant (that was later acquired by Abbott). Mr. Templin holds a B.S. in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology and an MBA from Duke.

What is Barry L. Templin's net worth?: The estimated net worth of Barry L. Templin is at least $1.90 million as of September 9th, 2026. Mr. Templin owns 94,826 shares of PROCEPT BioRobotics stock worth more than $1,903,158 as of September 11th. This net worth evaluation does not reflect any other investments that Mr. Templin may own. Learn More about Barry L. Templin's net worth.
How do I contact Barry L. Templin?: The corporate mailing address for Mr. Templin and other PROCEPT BioRobotics executives is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. PROCEPT BioRobotics can also be reached via phone at 650-232-7200 and via email at [email protected]. Learn More on Barry L. Templin's contact information.
Has Barry L. Templin been buying or selling shares of PROCEPT BioRobotics?: During the past quarter, Barry L. Templin has sold $7,814.35 in shares of PROCEPT BioRobotics stock. Most recently, Barry L. Templin sold 373 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $20.95, for a transaction totalling $7,814.35. Following the completion of the sale, the executive vice president now directly owns 94,826 shares of the company's stock, valued at $1,986,604.70. Learn More on Barry L. Templin's trading history.
Who are PROCEPT BioRobotics' active insiders?: PROCEPT BioRobotics' insider roster includes Antal Desai (Director), Frederic Moll (Director), Alaleh Nouri (EVP), Hisham Shiblaq (EVP, Chief Commercial Officer), Barry Templin (EXECUTIVE VP, CHIEF TECHNOLOGY OFFICER), Kevin Waters (EVP, CFO), Larry Wood (CEO), and Reza Zadno (CEO). Learn More on PROCEPT BioRobotics' active insiders.
Are insiders buying or selling shares of PROCEPT BioRobotics?: In the last twelve months, PROCEPT BioRobotics insiders bought shares 4 times. They purchased a total of 450,162 shares worth more than $10,981,406.16. In the last twelve months, insiders at the sold shares 12 times. They sold a total of 25,272 shares worth more than $623,796.88. The most recent insider tranaction occured on September, 9th when EVP Alaleh Nouri sold 297 shares worth more than $6,222.15. Insiders at PROCEPT BioRobotics own 4.0% of the company. Learn More about insider trades at PROCEPT BioRobotics.
Information on this page was last updated on 9/9/2026.

Barry L. Templin Insider Trading History at PROCEPT BioRobotics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2026	Sell	373	$20.95	$7,814.35	94,826
6/8/2026	Sell	358	$28.48	$10,195.84	68,953

Barry L. Templin Buying and Selling Activity at PROCEPT BioRobotics

PROCEPT BioRobotics Company Overview

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Today's Range

Now: $20.07

$19.76

$20.65

50 Day Range

MA: $20.26

$16.69

$22.89

2 Week Range

Now: $20.07

$16.67

$40.10

Volume

975,527 shs

Average Volume

937,787 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91